Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07107945) titled 'A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY(R) Kids)' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Boehringer Ingelheim
Condition:
Chronic Kidney Disease
Intervention:
Drug: Empagliflozin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 27, 2025
Target Sample Size: 120
Countries of Rec...